BR112019011350A2 - terapia de combinação - Google Patents
terapia de combinaçãoInfo
- Publication number
- BR112019011350A2 BR112019011350A2 BR112019011350A BR112019011350A BR112019011350A2 BR 112019011350 A2 BR112019011350 A2 BR 112019011350A2 BR 112019011350 A BR112019011350 A BR 112019011350A BR 112019011350 A BR112019011350 A BR 112019011350A BR 112019011350 A2 BR112019011350 A2 BR 112019011350A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunomodulatory agent
- type
- antibody
- antigen
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a uma combinação de um inibidor da proteína arginina metiltransferase tipo ii (prmt tipo ii) e agente imunomodulador, em que o agente imunomodulador é um anticorpo anti-ox40 ou um fragmento de ligação ao antígeno do mesmo. a presente invenção também fornece métodos para tratar câncer em um humano em necessidade de tratamento, compreendendo administrar ao ser humano uma combinação de um inibidor de prmt tipo ii e um agente imunomodulador, em que o agente imunomodulador é um anticorpo anti-ox40 ou um fragmento de ligação ao antígeno do mesmo, juntamente com ao menos um de: um carreador farmaceuticamente aceitável e um diluente farmaceuticamente aceitável, tratando assim o câncer no ser humano. a presente invenção fornece ainda uma composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de um inibidor de prmt tipo ii e uma segunda composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de um agente imunomodulador, em que o agente imunomodulador é um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428764P | 2016-12-01 | 2016-12-01 | |
| US201662433363P | 2016-12-13 | 2016-12-13 | |
| PCT/IB2017/057549 WO2018100535A1 (en) | 2016-12-01 | 2017-11-30 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019011350A2 true BR112019011350A2 (pt) | 2019-10-22 |
Family
ID=60782286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019011350A BR112019011350A2 (pt) | 2016-12-01 | 2017-11-30 | terapia de combinação |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3548068A1 (pt) |
| JP (1) | JP2020511407A (pt) |
| KR (1) | KR20190090823A (pt) |
| CN (1) | CN110234342A (pt) |
| AU (1) | AU2017369994A1 (pt) |
| BR (1) | BR112019011350A2 (pt) |
| CA (1) | CA3045243A1 (pt) |
| WO (1) | WO2018100535A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
| US20230301998A1 (en) * | 2020-05-04 | 2023-09-28 | Sanford Burnham Prebys Medical Discovery Institute | Methods and compositions for induction of antitumor immunity |
| EP4149483A4 (en) * | 2020-05-15 | 2024-09-11 | Fred Hutchinson Cancer Center | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY |
| CN113908283A (zh) * | 2021-09-30 | 2022-01-11 | 上海交通大学医学院附属新华医院 | Prmt5抑制剂及其与pd-l1抗体阻断剂联合在治疗肺癌上的应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| CN1328571B (zh) | 1998-12-23 | 2016-08-31 | 辉瑞大药厂 | 抗ctla-4的人单克隆抗体 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP3214175A1 (en) | 1999-08-24 | 2017-09-06 | E. R. Squibb & Sons, L.L.C. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CA2471392A1 (en) | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| ES2524694T3 (es) | 2002-10-17 | 2014-12-11 | Genmab A/S | Anticuerpos monoclonales humanos contra CD20 |
| US7521051B2 (en) | 2002-12-23 | 2009-04-21 | Medimmune Limited | Methods of upmodulating adaptive immune response using anti-PD-1 antibodies |
| ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20090311280A1 (en) | 2004-12-09 | 2009-12-17 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP1907424B1 (en) | 2005-07-01 | 2015-07-29 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007084559A2 (en) | 2006-01-13 | 2007-07-26 | Board Of Regents, The University Of Texas System | Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| KR20100054780A (ko) | 2007-06-18 | 2010-05-25 | 엔.브이.오가논 | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CA2949772A1 (en) | 2007-12-14 | 2009-06-25 | Pfizer Inc. | Binding molecules to the human ox40 receptor |
| WO2009114335A2 (en) * | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| KR20200047793A (ko) | 2008-12-09 | 2020-05-07 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| PL3279215T3 (pl) | 2009-11-24 | 2020-06-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| EP2933268B1 (en) | 2010-08-23 | 2017-07-12 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
| ES2708669T3 (es) | 2011-08-01 | 2019-04-10 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK |
| CN103946238B (zh) | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA3213528A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| MX370848B (es) | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP2935242A2 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| US9221794B2 (en) | 2012-12-21 | 2015-12-29 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| EP2935240A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US8993555B2 (en) * | 2012-12-21 | 2015-03-31 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| WO2016145150A2 (en) * | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
-
2017
- 2017-11-30 KR KR1020197018433A patent/KR20190090823A/ko unknown
- 2017-11-30 CN CN201780084564.XA patent/CN110234342A/zh active Pending
- 2017-11-30 WO PCT/IB2017/057549 patent/WO2018100535A1/en unknown
- 2017-11-30 EP EP17818288.7A patent/EP3548068A1/en not_active Withdrawn
- 2017-11-30 CA CA3045243A patent/CA3045243A1/en not_active Abandoned
- 2017-11-30 BR BR112019011350A patent/BR112019011350A2/pt not_active IP Right Cessation
- 2017-11-30 AU AU2017369994A patent/AU2017369994A1/en not_active Abandoned
- 2017-11-30 JP JP2019529614A patent/JP2020511407A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3548068A1 (en) | 2019-10-09 |
| CA3045243A1 (en) | 2018-06-07 |
| WO2018100535A1 (en) | 2018-06-07 |
| CN110234342A (zh) | 2019-09-13 |
| AU2017369994A1 (en) | 2019-06-13 |
| KR20190090823A (ko) | 2019-08-02 |
| JP2020511407A (ja) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011350A2 (pt) | terapia de combinação | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| BR112018075198A2 (pt) | método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit | |
| BR112018069732A2 (pt) | métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
| BR112018070302A2 (pt) | agentes que reconhecem o epítopo de clever-1 e usos dos mesmos | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112018002436A2 (pt) | tratamento de combinação de usos de métodos destes | |
| BR112019023909A2 (pt) | método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio. | |
| BR112018076639A2 (pt) | quimioterapias de combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2698 DE 20-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |